Dr. Ying Huang currently serves as Chief Executive Officer of Legend Biotech. He sits on the Board of Directors of Legend, as well as Quanta Therapeutics. Dr. Huang brings over 9 years of experience in research and development at major multi-national pharmaceutical companies and 12 years of experience as a biotechnology analyst on Wall Street. Dr. Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch where he led a team of analysts covering more than ...
Aug 10, 2022•24 min
Eli de los Pinos is the founding CEO of Aura, which she has created from the ground up: She developed the company concept and has spearheaded fundraising efforts, and today, she continues to lead Aura’s strategy and operations. Prior to founding Aura, she worked in Eli Lilly & Co.’s oncology business unit, where she was part of the leadership team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Eli worked as a post-doctor...
Aug 03, 2022•21 min
Brad Margus is co-founder and Executive Chairman of Cerevance, a drug discovery company advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease. The company's lead program, CVN424, has recently shown significant and clinically meaningful efficacy and safety in a 135-patient, phase 2 clinical study for Parkinson’s Disease. Investors include Takeda Pharmaceuticals, Google Ventures, Bill Gates, Casdin Cap...
Jul 27, 2022•23 min
Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic’s president and chief executive officer since May 2018. She joined Synlogic in September 2016 as chief medical officer. Prior to Synlogic, Aoife spent six years at Biogen, most recently as vice president and head of the Rare Disease Innovation Unit, developing programs from pre-clinical t...
Jul 20, 2022•30 min
Mr. Gergen was appointed Chief Executive Officer of Poseida in February 2022. He joined Poseida in February 2018, initially serving as Chief Business Officer and Chief Financial Officer before being named President and Chief Business Officer in July 2020. He has been a member of the Company’s board of directors since 2018. Mr. Gergen was previously the Senior Vice President and Chief Operating Officer of Halozyme, Inc. and Executive Vice President and Chief Operating Officer at Mirati Therapeuti...
Jul 13, 2022•30 min
Timothy J. Miller, Ph.D. CEO, President and Co-Founder Timothy Miller is CEO, President and Co-Founder of Forge Biologics, Inc., a VC-backed gene therapy development engine focused on accelerating access to potentially life-saving AAV gene therapies. Prior to founding Forge, Dr. Miller co-founded Abeona Therapeutics, a rare disease gene and cell therapy company. He served as Abeona’s CEO and President from 2012-early 2018, taking the company public in 2015. He is a proven biotech leader with exp...
Jun 29, 2022•22 min
Our guest this week is one of our hosts, Alok Tayi, and he has some exciting news. The official launch of his new company, Vibe Biotechnology, building a global community of patients, scientists, and partners around a shared mission to cure rare diseases. Vibe Bio's novel approach seeks to scale the development of treatments sustainably and provides patient communities unprecedented ownership over the results. Alok is a scientist by trade, with over 15 years under his belt including a PhD at Nor...
Jun 22, 2022•20 min
Paul is the CEO & Co-founder of Locus Biosciences. With a career that spans manufacturing, research & development, information technology and corporate transformations, Paul brings a broad range of experience and capability to deliver on the Locus vision. Prior to Locus, Paul was Chief Technology Officer at Patheon Pharmaceuticals and also held the role of Global Head of Operations for Patheon’s Pharmaceuticals Development Services business unit. Paul previously served as Global Head of ...
Jun 15, 2022•30 min
Dr. Trevor Martin founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based synthetic biology products across therapeutics and diagnostics, including a novel class of affordable, effective, and rapid CRISPR-enabled molecular diagnostics that allow individuals worldwide to better understand their health and a novel family of CRISPR Cas14 proteins that can enable in vivo editing. Trevor earned his BA from Princeton University and his Ph.D. in Biology from Stanford....
Jun 08, 2022•25 min
Laurence joined Decibel in January 2020. He previously served as an entrepreneur in residence at Third Rock Ventures, where he focused on novel drug discovery and development opportunities. Before that, Laurence was CEO of Warp Drive Bio, a small molecule company focused on novel oncology and antibiotic drug discovery based on natural products, until its merger with Revolution Medicines in 2018. Prior to that, he was the senior vice president and chief business officer of Alnylam Pharmaceuticals...
Jun 01, 2022•38 min
Ms. Zaderej has served as Axogen’s President, Chief Executive Officer, and a member of our Board of Directors since September 2011 and the Chairman of our Board of Directors since May 2018. Since May 2010, she has served as the Chief Executive Officer of Axogen’s wholly owned subsidiary, Axogen Corporation, and a member of the Board of Directors of Axogen Corporation. Ms. Zaderej joined Axogen Corporation in May 2006 and served as Vice President of Marketing and Sales from May 2006 to October 20...
May 25, 2022•26 min
John Glasspool is CEO and member of the Board of Directors of Anthos Therapeutics. Mr. Glasspool is also a member of the Board of Directors of Dalcor Corporation. He was formerly the Executive Vice President, Head of Corporate Strategy and Customer Operations at Baxalta Incorporated (NYSE: BXLT), formerly Baxter BioScience (NYSE: BAX). Prior to joining Baxter in August 2012, Mr. Glasspool was Head of Region Europe and Novartis Vaccines & Diagnostics (NYSE: NVS), a member of the V&D Execu...
May 18, 2022•24 min
Dr. Sullivan is co-founder and CEO of Vanqua. In addition, he has been a Venture Partner with Orbimed since January 2019. Previously, he was the Vice President of Research at Abbvie where he was responsible for the company’s research efforts in a variety of therapeutic/disease areas including oncology, immunology, neurology, hepatitis C and cystic fibrosis. Jim has advanced more than 100 compounds into clinical development across a number of disease states and technology platforms. These include...
May 11, 2022•22 min
Paula Soteropoulos brings to Ensoma more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization with P&L accountability, company building and organizational development. Her leadership throughout her career spans a broad range of therapeutic areas, including rare disease, cardiovascular and metabolism, infectious disease, renal, and transplant and oncology. In addition to Ensoma, Paula is a strategic a...
May 04, 2022•30 min
Jake Becraft is co-founder and CEO of Strand Therapeutics, an emerging biotechnology company at the forefront of mRNA therapeutics. With colleagues at MIT’s Synthetic Biology Center, he led the development of the world’s first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, and the Boston Business Journal, among others, for his vision and mission at Strand of applying this unique platform for real-world disease applications. Jake was recently...
Apr 27, 2022•1 hr 6 min
Tim Sweeney, MD, PhD, is co-founder and CEO of Inflammatix. Tim has extensive experience in medical practice (general & trauma surgery), bench research, and bioinformatics / machine learning. While training at Stanford he helped invent the core technology on which Inflammatix is based, is named on over a dozen patents related to medical diagnostics, and has published >100 manuscripts & abstracts. He is PI (through Inflammatix) on multiple development contracts from DARPA, BARDA, and N...
Apr 20, 2022•20 min
Al leads teams in early-stage discovery up through non-clinical development, identifying new drug candidates for advancement into clinical research. Al joined Sage as CSO in 2011, with more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Most recently, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck USA, where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synapti...
Apr 13, 2022•19 min
Dr. Stuart Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the Board of Directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. PTC now has a footprint in more than 50 countries, wit...
Apr 06, 2022•28 min
Patrick Kleyn joined Rhythm in 2018 with over 25 years’ experience in human genetics and genomics, and he was named as head of TRAD in 2021. Prior to joining Rhythm, Patrick has held leadership roles in academia, biotech and large pharmaceutical companies, as his work has focused on the application of genomic technologies for drug and biomarker discovery and development. He began his career at Millennium Pharmaceuticals initially working on obesity target discovery and ultimately leading the gen...
Mar 30, 2022•20 min
Jacob(Jake)Rubens, Co-Founder, Chief Innovation Officer Jake is Co-Founder and Chief Innovation Officer of Tessera Therapeutics, as well as a Principal at Flagship Pioneering. Jake joined Flagship Pioneering in 2015 and works as part of a venture-creation team, founding and growing companies based on new biotechnology. At Flagship, Jake launched Kaleido Biosciences and co-founded Sana Biotechnology. Jake was the Head of Innovation at Cobalt Biomedicine, where he invented and developed the compan...
Mar 23, 2022•26 min
Kleanthis is a serial biotechnology entrepreneur with over two decades of experience in the biotechnology and pharmaceutical research industries as an executive, company founder, chief executive officer, investor and board member. Dr. Xanthopoulos has founded five companies, introduced three life science companies to NASDAQ and financed and brokered numerous creative strategic alliance and partnership deals with large pharmaceutical partners. In addition to his role at Shoreline Biosciences, Dr....
Mar 16, 2022•25 min
David Berry is the Founder and CEO of Valo and since 2005, has served as General Partner at Flagship Pioneering, having founded over 25 companies including Indigo Agriculture, Seres Therapeutics (NASDAQ: MCRB), Eleven Biotherapeutics (NASDAQ: EBIO), T2 Biosystems (NASDAQ: TTOO), Evelo Biosciences (NASDAQ: EVLO), Axcella Health (NASDAQ: AXLA), and Joule Unlimited. David played an instrumental role in the conception and implementation of Flagship Labs, which is the foundation of all of its compani...
Mar 09, 2022•33 min
A serial entrepreneur in software and biotech, Yochi Slonim has built multiple companies as a founder and CEO through all phases of growth all the way to IPOs and large M&A exits. As a Co-founder and CEO of Anima Biotech, he is driving the company's vision and strategy, fundraising, and partnering. Prior to Anima, Yochi was a co-founder of Mercury Interactive. As CTO and VP R&D from the company's early days, he created product vision and strategy and led a multi-product organization of 2...
Mar 02, 2022•40 min
Lovisa Afzelius is an origination partner at Flagship Pioneering and the former SVP of Strategy & Operations at Flagship-founded Cogen Immune Medicines, now known as Repertoire Immune Medicines. A computational scientist by training, she has two decades of leadership experience and a passion for data-driven drug discovery, from early inception to clinical development across multiple therapeutic areas. Previously, Lovisa built and led Pfizer’s systems immunology function and served as executi...
Feb 23, 2022•29 min
James Mackay, PhD, Founder, President and Chief Executive Officer, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. Prior to founding Aristea, he was President and Chief Executive Officer of Ardea Biosciences, Inc., following the company’s acquisition by AstraZeneca in 2012. James was instrumental to setting up an innovative model for Ardea Biosciences that retained the biotech’s...
Feb 16, 2022•25 min
A physician-scientist, her groundbreaking work in vascular and lung engineering has made Dr. Niklason a world leader in regenerative medicine. She is a member of the National Academies of Engineering and Medicine. Dr. Niklason is the founder of Humacyte and has served as President and Chief Executive Officer since November 2020 and as a member of the Humacyte Board since 2004. Dr. Niklason holds a Ph.D. in Biophysics from the University of Chicago and an M.D. from the University of Michigan.
Feb 09, 2022•34 min
Dr. Fordyce brings more than 15 years’ experience leading teams in drug discovery, development, clinical translation, and commercialization of new treatments. Before founding Vera, Fordyce was the founder and CEO of gene-editing company Trucode Gene Repair, Inc., having previously served as an entrepreneur in residence at Kleiner Perkins Caufield and Byers. Earlier in his career, Fordyce served as Senior Director of clinical research at Gilead Sciences, Inc., where he contributed to seven new dr...
Feb 02, 2022•20 min
Dr. Schneider is the Chief Operating Officer for Solid Biosciences, responsible for overseeing corporate and technical operations, quality, patient advocacy, communications, corporate strategy, and human resources. As Solid’s first employee in 2014, Dr. Schneider was instrumental in discovering and executing proof-of-concept studies for SGT-001, as well as building the company’s unique disease-focused business model. In his role as Chief Operating Officer, Dr. Schneider oversees corporate and te...
Jan 26, 2022•35 min
Patricia (Trish) Hurter, Dr. Patricia Hurter is CEO of Lyndra Therapeutics. Prior to Lyndra, Dr. Hurter was Senior Vice President of Pharmaceutical and Preclinical Sciences at Vertex Pharmaceuticals, Inc. She also served as Interim Head of Global Regulatory Affairs from 2013-2014 and oversaw several label expansions for Kalydeco® and the submission of the new drug application for Orkambi®. She played a leadership role in the development and commercialization of 5 transformative therapies for Ver...
Jan 19, 2022•31 min
Shawn M. Leland is the Founder and Chief Executive Officer of Elevation Oncology overseeing all day-to-day operations. Shawn brings over a decade of experience in medical affairs and business development for the pharmaceutical/biotech industry, with a focus on building collaborations to realize the full potential of targeted and personalized therapeutics. Shawn has been involved in global transactions totaling more than $450 million in upfront payments and milestone payments at Eli Lilly, ARIAD ...
Jan 12, 2022•26 min
